Janux Therapeutics (NASDAQ:JANX) Rating Lowered to “Sell” at Wall Street Zen

Janux Therapeutics (NASDAQ:JANX) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Several other analysts have also recently weighed in on the stock. Wedbush reissued an “outperform” rating and issued a $45.00 price objective (down from $76.00) on shares of Janux Therapeutics in a research note on Tuesday, December 2nd. HC Wainwright cut their target price on Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating on the stock in a report on Tuesday, December 2nd. Stifel Nicolaus reduced their price target on Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, December 2nd. Barclays decreased their price target on Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, December 17th. Finally, Cantor Fitzgerald lowered their price objective on Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating for the company in a research report on Friday, February 27th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $56.91.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX opened at $13.18 on Friday. The company has a 50 day simple moving average of $13.68 and a 200 day simple moving average of $19.26. Janux Therapeutics has a 1 year low of $12.12 and a 1 year high of $35.34. The firm has a market cap of $801.74 million, a PE ratio of -7.20 and a beta of 2.88.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, February 26th. The company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.14. The business had revenue of $7.88 million for the quarter, compared to the consensus estimate of $0.08 million. As a group, research analysts anticipate that Janux Therapeutics will post -1.38 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Andrew Hollman Meyer sold 1,879 shares of the business’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $25,798.67. Following the transaction, the insider owned 83,095 shares in the company, valued at $1,140,894.35. The trade was a 2.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Zachariah Mciver sold 2,714 shares of the stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $13.73, for a total value of $37,263.22. Following the sale, the insider owned 23,286 shares of the company’s stock, valued at approximately $319,716.78. The trade was a 10.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 19,033 shares of company stock valued at $261,323 over the last quarter. Company insiders own 29.40% of the company’s stock.

Institutional Investors Weigh In On Janux Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC lifted its stake in Janux Therapeutics by 230.0% in the second quarter. Squarepoint Ops LLC now owns 189,569 shares of the company’s stock valued at $4,379,000 after buying an additional 132,121 shares during the period. Aberdeen Group plc grew its position in shares of Janux Therapeutics by 21.1% during the 3rd quarter. Aberdeen Group plc now owns 345,476 shares of the company’s stock worth $8,443,000 after buying an additional 60,188 shares during the period. Geode Capital Management LLC increased its stake in shares of Janux Therapeutics by 15.5% in the 2nd quarter. Geode Capital Management LLC now owns 902,312 shares of the company’s stock valued at $20,845,000 after acquiring an additional 121,403 shares in the last quarter. Capital Fund Management S.A. bought a new stake in shares of Janux Therapeutics in the 2nd quarter valued at $757,000. Finally, Congress Asset Management Co. acquired a new position in shares of Janux Therapeutics during the 3rd quarter valued at $1,363,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.